Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01544010 · ClinicalTrials.gov registry record · NA
Optimal TTM Tailoring for Population Cessation
A NA study, sponsored by University of Rhode Island.
- Completed
- Registry status
- NA
- Development phase
- 3,006
- Enrollment target
NCT01544010: Completed NA study, sponsored by University of Rhode Island.
NCT01544010 is a NA study that has completed, run by University of Rhode Island. The registered enrollment target is 3,006 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (114% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01544010, a NA study, has completed, sponsored by University of Rhode Island.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,006 participants
- Enrollment target
Study Summary
This study explored optimal tailoring strategies for population tobacco cessation in 4 treatment groups and a control group over 24 months. Transtheoretical model (TTM) tailored feedback on all 14 variables has been found to be a robust population cessation strategy across studies. This proposal sought to find a subset of these variables that is optimal for tailoring, both minimizing response burden while maximizing effectiveness. Addiction variables have been demonstrated to predict smoking outcomes across studies as well, so we will integrate tailored feedback using TTM and addiction variables into an enhanced tailoring group. Optimally tailored feedback that both helps unmotivated smokers reduce their addiction and helps motivated smokers quit could lead to a breakthrough in population cessation.
Primary Outcome
Self-report point prevalence abstinence
Interventions
- BEHAVIORAL Stage-Tailored Manual
- BEHAVIORAL Stage Tailored Feedback Report
- BEHAVIORAL Moderate TTM-Tailored Feedback Report
- BEHAVIORAL Full TTM-Tailored Feedback Report
- BEHAVIORAL Enhanced TTM+Addiction Tailored Feedback Report
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,006 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-06 |
| Phase | NA |
What the finished NCT01544010 record still lists
NCT01544010 is an interventional study that assigns participants to a tested intervention. Its 3,006 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (114% higher).
The record links to 0 conditions, and to 5 interventions - of which Stage-Tailored Manual is the first listed.
NCT01544010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01544010 about?
NCT01544010 is a clinical study titled "Optimal TTM Tailoring for Population Cessation". This study explored optimal tailoring strategies for population tobacco cessation in 4 treatment groups and a control group over 24 months. Transtheoretical model (TTM) tailored feedback on all 14 variables has been found to be a robust population cessation strategy across studies. This proposal sou...
What is the current status of trial NCT01544010?
This trial is currently completed. It is a NA study. The enrollment target is 3,006 participants. The study started on 2009-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01544010?
The interventions under investigation include: Stage-Tailored Manual (BEHAVIORAL), Stage Tailored Feedback Report (BEHAVIORAL), Moderate TTM-Tailored Feedback Report (BEHAVIORAL), Full TTM-Tailored Feedback Report (BEHAVIORAL), Enhanced TTM+Addiction Tailored Feedback Report (BEHAVIORAL).
Who is sponsoring clinical trial NCT01544010?
This trial is sponsored by University of Rhode Island, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01544010's enrollment target sits among peer trials
3,006 40th of 2000 higher than 1,961 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia